Page last updated: 2024-08-23

bromocriptine and cabergoline

bromocriptine has been researched along with cabergoline in 199 studies

Research

Studies (199)

TimeframeStudies, this research(%)All Research%
pre-19905 (2.51)18.7374
1990's36 (18.09)18.2507
2000's66 (33.17)29.6817
2010's71 (35.68)24.3611
2020's21 (10.55)2.80

Authors

AuthorsStudies
Audinot, V; Boutin, JA; Cussac, D; Maiofiss, L; Millan, MJ; Newman-Tancredi, A1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Demedts, M; Dom, R; Frans, E1
Crosignani, P; D'Alberton, A; de Vincentiis, S; Ferrari, C; Mattei, AM; Paracchi, A1
Barone, D; Benedetti, MS; Dostert, P; Efthymiopoulos, C; Peretti, G; Roncucci, R1
Casazza, S; D'Alberton, A; de Vincentiis, S; Fadin, M; Giorda, G; Motta, T1
Dominoni, P; Ferrari, L; Gianola, D; Gualteroni, L; Montini, M; Pagani, G; Pagani, MD; Sileo, F; Stroppa, S; Tengattini, F1
Camanni, F; Ciccarelli, E; Giordano, G; Giusti, M; Miola, C; Potenzoni, F; Sghedoni, D1
Baroldi, P; Cavioni, V; Crosignani, PG; Ferrari, C; Galparoli, C; Gerevini, G; Mattei, AM; Paracchi, A; Romano, C; Spellecchia, D1
Cancio, E; Cocchi, D; Dall'Ara, A; Devesa, J; Di Salle, E; Lima, L; Müller, EE1
Barbieri, C; Boghen, M; Caldara, R; Codecasa, F; Dubini, A; Ferrari, C; Mucci, M; Paracchi, A; Romano, C1
Zaccheo, T1
Arvigo, M; Barreca, A; Cariola, G; Foppiani, L; Giordano, G; Minuto, F; Ponzani, P1
Arita, K; Eguchi, K; Ito, A; Kawamoto, K; Kurisu, K; Uozumi, T2
Bryson, HM; Fitton, A; Rains, CP1
Riva di Sanseverino, L; Sabatino, P; Tonani, R1
Bosc, M; Leclere, J; Pascal-Vigneron, V; Weryha, G1
Mark, MH; Sage, JI1
Fraser, RB; Jones, TH1
Ferrari, CI; Ismail, I; Piscitelli, G; Polli, A; Scanlon, MF; Webster, J1
Serri, O1
Colombo, N; D'Alberton, A; de Vincentiis, S; Marchini, M; Motta, T1
Crosignani, PG; Ferrari, C; Piscitelli, G1
Arai, N; Fukuyama, J; Isaji, M; Kuno, S; Miyata, H; Mizuta, E1
Delgrange, E; Donckier, J; Maiter, D1
Webster, J1
Catz, T; Inzelberg, R; Kippervasser, S; Korczyn, AD; Nisipeanu, P; Orlov, E; Rabey, JM; Schechtman, E1
Arai, N; Isaji, M; Itoh, F; Kojima, M; Miyagi, M; Taya, F; Ujiie, A1
Cerbone, G; Cirillo, S; Colao, A; Di Sarno, A; Ferone, D; Lombardi, G; Marzullo, P; Merola, B; Sarnacchiaro, F1
Korczyn, AD; Nisipeanu, P1
Marsden, CD1
Colao, A; Di Sarno, A; Di Somma, C; Facciolli, G; Klain, M; Landi, ML; Lombardi, G; Panza, N; Pivonello, R; Salvatore, M1
Conner, P; Fried, G1
Colao, A; De Rosa, M; Di Sarno, A; Ferone, D; Landi, ML; Lombardi, G; Merola, B; Paesano, L; Zarrilli, S1
Crabbé, J; Delgrange, E; Donckier, J1
Chervin, A; Fideleff, HL; Gurucharri, C; Holland, ME; Sinai, I1
Inada, Y; Kojima, M; Komatsu, H; Miyata, H; Moro, M; Torii, R1
Abs, R; Beckers, A; Coremans, P; Lamberigts, G; Mahler, C; Maiter, D; Mockel, J; Petrossians, P; Raftopoulos, C; Stevenaert, A; van den Bruel, A; Vandeweghe, M; Velkeniers, B; Verhelst, J; Verlooy, J1
Montastruc, JL; Rascol, O; Senard, JM1
Atkin, SL; Foy, PM; Hadden, DR; Leong, KS; MacFarlane, IA; Swift, AC1
Colao, A; Di Sarno, A; Di Somma, C; Klain, M; Loche, S; Lombardi, G; Pietrosante, M; Pivonello, R; Salvatore, M1
Brannan, T; Prikhojan, A; Yahr, MD1
Tollin, SR1
De Santis, L; Doldi, N; Ferrari, A; Papaleo, E1
Agostini, S; Billeci, D; Conte, N; De Menis, E; Marton, E; Tramontin, P; Visentin, A1
Clarke, CE; Deane, KD1
de la Sota, RL; Gobello, C; Goya, RG1
Atkinson, AB; Bell, PM; Courtney, CH; Ellis, PK; Hadden, DR; Leslie, H; McCance, DR; Sheridan, B1
Arikan, E; Hatemi, H; Sabuncu, T; Tasan, E1
Cappabianca, P; Colao, A; Di Salle, F; Di Sarno, A; Di Somma, C; Faggiano, A; Landi, ML; Lombardi, G; Pivonello, R; Rossi, FW1
Colao, A; di Sarno, A; di Somma, C; Lombardi, G; Pivonello, R1
Liu, C; Tyrrell, JB1
Freed, DJ; Gillam, MP; Middler, S; Molitch, ME1
Gekht, AB1
Mah, PM; Webster, J1
Cavallero, D; Fazzuoli, L; Giusti, M; Valenti, S1
Goadsby, PJ; Levy, MJ; Matharu, MS1
Fujinami, A; Kuno, S; Matsui, H; Mizuta, I; Ohta, K; Ohta, M1
Bankowski, BJ; Zacur, HA1
Broglia, G; Castex, G; Corrada, Y; Gobello, C1
Ball, SG; Hall, K; James, RA; Kendall-Taylor, P; Pearce, SH; Quinton, R; Sibal, L; Ugwu, P1
Molitch, ME4
Braucks, GR; Gadelha, MR; Naliato, EC; Tabet, AL; Violante, AH1
Chang, JY; Kattah, JC; Orth, EH; Talkad, AV; Xu, MY1
Hotta, M; Kamo, T; Kawakami, M; Nemoto, S; Oshima, J; Shimojo, S; Shiraishi, M; Sugihara, H; Takahashi, Y; Yasaki, S1
Couldwell, WT; Liu, JK1
Grosset, D; Grosset, K; Macphee, G; Needleman, F1
Baran, AS; Rack, MJ; Richert, AC; Roffwarg, HP1
Basu, S; Chaudhuri, KR; Dhawan, V; Jackson, G; Odin, P1
Trifonov, I1
Casulari, LA; Mello, PA; Naves, LA; Papadia, C; Pereira Neto, A1
Brooks, PL; Vella, ET; Wynne-Edwards, KE1
Newell-Price, J; Ross, R; Selvarajah, D; Webster, J1
Goetz, CG; Poewe, W; Rascol, O; Sampaio, C1
Abs, R; Verhelst, J1
Goadsby, PJ; Levy, MJ; Matharu, MS; Meeran, K; Powell, M1
Howell, DL; Hudgins, RJ; Mazewski, CM; Meacham, LR; Wasilewski, K1
Biswas, M; Davies, JS; Evans, LM; Jadon, D; McEwan, P; Rees, DA; Scanlon, MF; Smith, J1
Crosignani, PG1
Góth, MI; Iván, G; Nagy, GM; Oláh, M; Szigeti-Csúcs, N1
Bronstein, MD2
Boulos, PT; Hamilton, DK; Laws, ER; Vance, ML1
Barlier, A; Jaquet, P1
Colao, A; De Leo, M; Di Sarno, A; Guerra, E; Lombardi, G; Mentone, A1
Burger, E; Härtter, S; Kvernmo, T1
Mascarell, S; Sarne, DH1
Tokhunts, KA1
Colao, A; Di Somma, C; Lombardi, G; Pivonello, R; Savastano, S; Tauchmanovà, L1
Chuang, E; Molitch, ME1
Greenman, Y1
Horikawa, F; Kawabata, Y; Miki, N; Miyake, H; Ono, M; Ueno, Y1
Caldas, D; Cesar de Oliveira Naliato, E; Colao, A; Dutra Violante, AH; Fontes, R; Gomes de Souza, R; Guerra, E; Lamounier Filho, A; Rezende Loureiro, C; Schrank, Y; Sebastian, A; Vaisman, M1
Daida, H; Hatano, T; Hattori, N; Iwama, Y; Komine-Kobayashi, M; Mizuno, Y; Mochizuki, H; Nakayama, T; Sakai, M; Urabe, T; Yamashiro, K1
Acharya, SV; Bandgar, TR; Gopal, RA; Joshi, SR; Menon, PS; Shah, NS1
Doi, K; Isono, T; Kawamura, T; Kitagawa, N; Kuno, S; Masaki, M; Mizuta, E; Oeda, T; Sawada, H; Taniguchi, S; Yaku, H; Yamamoto, K; Yutani, C1
Andersohn, F; Garbe, E1
Martin, NM; Meeran, K; Tan, T1
Fujioka, S; Iwamoto, K; Kawamura, M; Nakajima, M; Ohno, H1
Pullan, PT1
Bahuleyan, B; Easwer, HV; Krishna, K; Menon, G; Nair, S; Rao, BR1
Ajitkumar, G; Ghosh, KN; Mercy, KA; Praseeda, R; Sreekumaran, T1
Albuquerque, JL; Azevedo, MF; Boguszewski, CL; Bronstein, MD; Casulari, LA; de Oliveira, AR; Dos Santos Faria, M; Gadelha, MR; Montenegro, RM; Musolino, NR; Naves, LA; Pinho Barbosa, FR; Ramos, AJ; Serfaty, FM; Vilar, L1
Atis, A; Aydin, Y; Goker, N; Kaleli, S; Uludağ, S1
Amano, K; Hori, T; Izumi, S; Kawamata, T; Makino, R; Miki, N; Okada, Y; Ono, M; Seki, T; Takano, K1
Klibanski, A1
Bahceci, M; Sismanoglu, A; Ulug, U1
Babakhani, L; Fereshtehnejad, SM; Mojthahedi, K; Motazedian, S1
Barbosa, FR; Domingues, RC; dos Santos Silva, CM; Fontes, R; Gadelha, MR; Lima, GA; Warszawski, L1
Burger, P; Menucci, M; Quiñones-Hinojosa, A; Salvatori, R1
Freudenmann, RW; Gahr, M; Kölle, MA1
Boguszewski, CL; dos Santos Nunes, V; El Dib, R; Nogueira, CR1
Adamidou, F; Anagnostis, P; Efstathiadou, Z; Karathanassi, E; Kita, M; Polyzos, SA1
Azevedo, M; Boguszewski, CL; de Souza, AM; dos Santos, CM; Marini, LC; Sakamoto, KS1
Bernard, N; Descotes, J; Gillet, A; Gouraud, A; Mirkou, A; Suchovsky, D; Vial, T1
Abad, A; Aller, J; Batista, E; Doltra, A; García-Pavía, P; Halperin, I; Lucas, T; Mirelis, JG; Mora, M; Puig-Domingo, M; Santos, AE; Sitges, M; Varela, C1
Elenkova, A; Kalinov, K; Shabani, R; Zacharieva, S1
Berardini, A; Biagini, E; Graziosi, M; Pazzi, C; Rapezzi, C; Rosmini, S1
Bilge, A; Kurtulmus, N; Yarman, S1
Deukmedjian, AR; Hann, S; Morrison, AD; Shah, V; Vale, FL1
Bancroft, T; Burton, T; Le Nestour, E; Neary, M1
Ahtiainen, P; Calandra, RS; Di Giorgio, NP; Gonzalez, B; Huhtaniemi, IT; Poutanen, M; Ratner, LD; Rulli, SB1
Alkabbani, A; Doshi, K; Hamrahian, A; Hatipoglu, B; Kennedy, L; Makin, V; Mon, SY; Olansky, L; Thorton, JN; Weil, R1
Abaci, A; Altincik, A; Bober, E; Buyukgebiz, A; Can, S; Catli, G; Demir, K1
Hashida, H; Hattori, N; Iijima, M; Kano, O; Kubo, S; Matsumura, M; Murakami, H; Nanri, K; Okuma, Y; Suzuki, M; Suzuki, Y; Tomimitsu, H; Utsumi, H1
Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ1
Góth, M1
Cuevas, JL; Fernández, V; González, O; Rojas, D; Torche, E; Wohllk, N1
Hisanaga, R; Nakamura, M; Nomoto, S; Sato, T1
Descamps, P; Jeanneteau, P; Mercier, MB; Parot-Schinkel, E; Sentilhes, L1
Barkan, A; Benbassat, C; Bronstein, MD; Shapiro, J; Shimon, I; Tsvetov, G1
Figueroa-Núñez, C; González, E; Gutierrez, M; Hernán Martínez, J; Mangual-García, M; Mansilla-Letelier, P; Miranda, Mde L; Palermo-Garofalo, C; Sánchez, A; Santiago, M; Torres, O; Trinidad, R1
Bonadei, I; Curnis, A; D'Aloia, A; Metra, M; Piovanelli, B; Rovetta, R; Vizzardi, E1
Beketić-Orešković, L; Ježek, D; Kasum, M; Orešković, S; Pekez, M; Stanić, P; Vrčić, H1
Krysiak, R; Okopien, B1
Aydogan, U; Cengiz, M; Ercan, CM; Ergun, A; Ide, T; Kayaalp, O; Keskin, U; Yumusak, N1
Akbaba, G; Arduc, A; Aydin, Y; Berker, D; Gokay, F; Guler, S; Isik, S; Kucukler, FK; Ozuguz, U; Tutuncu, Y1
Elenkova, A; Gerenova, J; Hristozov, K; Kalinov, K; Kamenov, Z; Kirilov, G; Marinov, M; Natchev, E; Orbetzova, M; Tcharaktchiev, D; Tsinlikov, I; Vandeva, S; Yaneva, M; Zacharieva, S1
Cámara Gómez, R; Del Olmo García, M; Merino Torres, JF; Querol Ripoll, R; Simal Julián, JA1
Couldwell, WT; Eloy, JA; Liu, JK; Wong, A1
Krysiak, R; Okopien, B; Okrzesik, J1
Couldwell, WT; Eloy, JA; Hajart, AF; Jethwa, PR; Liu, JK; Patel, TD1
Lamos, EM; Levitt, DL; Munir, KM1
Dogansen, SC; Selcukbiricik, OS; Tanrikulu, S; Yarman, S1
Alfieri, A; Ballarino, MC; Boero, L; Chervin, A; Danilowicz, K; Diez, S; Fainstein Day, P; García-Basavilbaso, N; Glerean, M; Guitelman, M; Katz, D; Loto, MG; Mallea-Gil, MS; Manavela, M; Martinez, M; Miragaya, K; Moncet, D; Rogozinski, AS; Servidio, M; Stalldecker, G; Vitale, M1
Bronstein, MD; Espinosa, E; Glezer, A; Greenman, Y; Mendoza, V; Mercado, M; Popovic, V; Shimon, I; Sosa, E; Tirosh, A1
Cooper, O; Gertych, A; Greenman, Y; Jonas-Kimchi, T; Melmed, S; Ram, Z; Robenshtok, E; Sagiv, N; Shimon, I; Stern, N; Yaish, I; Yuan, X1
Blankley, G; Galbally, M; Power, J; Snellen, M1
Chapman, IM; De Sousa, SM; Falhammar, H; Torpy, DJ1
Atkinson, JL; Donegan, D; Erickson, B; Erickson, D; Jentoft, M; Meyer, F; Natt, N; Nippoldt, TB1
Andereggen, L; Andres, RH; Beck, J; Christ, E; El-Koussy, M; Frey, J; Seiler, RW1
Hart, RJ; Mourad, S; Tang, H; Zhai, SD1
Dhanjal, MK; Knight, M; Lambert, K; McCance, DR; Rees, K; Seed, PT; Williamson, C1
Beckers, A; Bonneville, JF; Brue, T; Castinetti, F; Cuny, T; Dufour, H; Eroukhmanoff, J; Potorac, I; Tejedor, I; Touraine, P; Weryha, G1
Carvalho, D; Souteiro, P; Teixeira, M1
Araujo, B; Belo, S; Carvalho, D1
Ji, MJ; Kim, JH; Kim, SY; Kim, YH; Lee, JH; Paek, SH; Shin, CS1
Cha, HJ; Kim, JH; Kim, SW; Kim, YH; Lee, JH; Lee, SY; Paek, SH; Shin, CS1
Čehić, E; Franulić, D; Grgić, F; Kasum, M; Lila, A; Orešković, S; Vujić, G1
Bilbao, I; Egaña, N; García, C; Olaizola, I1
Ahangari, G; Bakhtou, H; Deezagi, A; Olfatbakhsh, A1
Huang, HY; Lin, SJ; Wu, ZB; Zhao, WG1
Arlt, W; Ayuk, J; Fountas, A; Gittoes, N; Karavitaki, N; Santharam, S; Tampourlou, M; Toogood, A1
Huang, HY; Hui, GZ; Tang, H; Wu, ZB; Zhai, W1
Maiter, D1
Cong, Z; Luo, X; Ma, C; Sun, R; Tang, C; Wen, G; Yang, J; Zhong, C; Zhu, J1
Akinduro, OO; Bernet, V; Chaichana, KL; De Biase, G; Donaldson, A; Izzo, A; Lu, VM; Meyer, FB; Olomu, O; Quinones-Hinojosa, A; Van Gompel, JJ; Vilanilam, G1
Colwell, HH; Fleseriu, M; Fogelfeld, L; Gordon, MB; Haviv, A; Ludlam, WH; Mathias, SD; Sisco, J1
Farrant, MT; Gunn, AJ; Milsom, SR; O'Sullivan, SM; Ogilvie, CM1
Okayama, A; Sato, T; Shimatsu, A; Yamaguchi, H1
Kawakami, K; Matsubayashi, K1
Hart, RJ; Mourad, SM; Tang, H; Wang, A; Zhai, SD1
Biermasz, NR; Chanson, P; Jorgensen, JOL; Kuhn, E; Weinreich, AA1
Abd El Latif, HA; El Yamani, M; Fouad Shalaby, MA; Galal, MA; Kamal, S; Masaood, R; Sindi, I1
Chen, S; Dong, J; Gu, J; Jiang, X; Li, D; Wen, X; Zou, Y1
Cai, X; Cong, Z; Ma, C; Tang, C; Yang, J; Yuan, F; Zhu, J1
Auriemma, RS; Colao, A; Negri, M; Patalano, R; Pirchio, R; Pivonello, C; Pivonello, R1
Canturk, S; Dogansen, S; Hacisahinogullari, H; Yarman, S1
Kasica, N; Mackiewicz, J; Osęka, M; Saładziak, K; Święch, A1
Akhtar, MF; Akter, R; Al-Harrasi, A; Berrada, M; Bhatia, S; Damiri, F; Ferdous Mitu, J; Kabir, MT; Rahman, MH; Rahman, MS; Saleem, A1
Inder, WJ; Jang, C1
Hamidianjahromi, A; Tritos, NA1
Auriemma, RS; Colao, A; Graziadio, C; Pirchio, R; Pivonello, R1
Bauersachs, J; Berliner, D; Erschow, S; Haebel, L; Hilfiker-Kleiner, D; Koenig, T; Mueller, JH; Pfeffer, TJ; Ricke-Hoch, M; Scherr, M; Talbot, SR; Yalman, KC; Zwadlo, C1
Arastu, MI; Curiale, AM; Lipton, BA; Longo, S; Nanda, S; Tessier, S1
Huang, Q; Li, M; Tan, J; Zeng, Y; Zhou, W; Zou, Y1
Cescato, VAS; Cunha-Neto, MBC; Glezer, A; Musolino, NRC; Pinheiro, FMM; Silva, GO; Stumpf, MAM1
Miller, KK; Tritos, NA1
Attanasio, R; Basile, M; Bozzao, A; Cappabianca, P; Caputo, M; Cozzi, R; Cruciani, F; De Menis, E; Doglietto, F; Esposito, F; Ferrante, E; Ferraù, F; Grimaldi, F; Iatì, G; Lania, AG; Laureti, S; Lello, S; Locatelli, D; Maffei, P; Mazzatenta, D; Minniti, G; Mitrova, Z; Paoletta, A; Papini, E; Peri, A; Persichetti, A; Poggi, M; Rudà, R; Ruini, C; Samperi, I; Saulle, R; Scoppola, A; Settanni, F; Silvani, A; Simona Auriemma, R; Tortora, F; Vecchi, S; Veronese, N1

Reviews

52 review(s) available for bromocriptine and cabergoline

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
New drugs for hyperprolactinaemia.
    Drug and therapeutics bulletin, 1995, Volume: 33, Issue:9

    Topics: Aminoquinolines; Bromocriptine; Cabergoline; Clinical Trials as Topic; Ergolines; Hormone Antagonists; Humans; Hyperprolactinemia

1995
Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
    Drugs, 1995, Volume: 49, Issue:2

    Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Hyperprolactinemia; Lactation; Prolactin; Tissue Distribution

1995
Cabergoline: a new drug for the treatment of hyperprolactinaemia.
    Human reproduction (Oxford, England), 1995, Volume: 10, Issue:7

    Topics: Bromocriptine; Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Ergolines; Female; Humans; Hyperprolactinemia; Lactation; Postpartum Period; Randomized Controlled Trials as Topic

1995
A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.
    Drug safety, 1996, Volume: 14, Issue:4

    Topics: Aminoquinolines; Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Lactation; Male; Pregnancy

1996
Newer therapies for Parkinson's disease.
    Neurologia i neurochirurgia polska, 1996, Volume: 30 Suppl 2

    Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Indoles; Parkinson Disease

1996
Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
    Drugs, 1998, Volume: 55 Suppl 1

    Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic

1998
Hyperprolactinemia; etiology, diagnosis and treatment alternatives.
    Acta obstetricia et gynecologica Scandinavica, 1998, Volume: 77, Issue:3

    Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Pergolide; Prolactin; Receptors, Prolactin

1998
Treatment of Parkinson's disease should begin with a dopamine agonist.
    Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:5

    Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Indoles; Levodopa; Lisuride; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D2; Thiazoles

1999
CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas.
    Clinical endocrinology, 2000, Volume: 52, Issue:1

    Topics: Adult; Bromocriptine; Cabergoline; Cerebrospinal Fluid Rhinorrhea; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Tomography, X-Ray Computed

2000
Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    The Cochrane database of systematic reviews, 2001, Issue:1

    Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic

2001
Dopamine receptor agonists for treating prolactinomas.
    Expert opinion on investigational drugs, 2002, Volume: 11, Issue:6

    Topics: Aminoquinolines; Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Ergot Alkaloids; Female; Humans; Pergolide; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma

2002
DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17 Suppl 4

    Topics: Benzophenones; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Nitrophenols; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Tolcapone

2002
[Use of dopamine agonists in the treatment of Parkinson's disease].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2002, Volume: 102, Issue:9

    Topics: Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Controlled Clinical Trials as Topic; Dopamine Agonists; Ergolines; Humans; Indoles; Lisuride; Parkinson Disease; Pergolide; Piribedil; Placebos; Pramipexole; Serotonin Receptor Agonists; Thiazoles; Time Factors

2002
Hyperprolactinemia: etiology, diagnosis, and management.
    Seminars in reproductive medicine, 2002, Volume: 20, Issue:4

    Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Neurosurgical Procedures; Prevalence

2002
Dopamine agonist therapy for hyperprolactinemia.
    Clinical obstetrics and gynecology, 2003, Volume: 46, Issue:2

    Topics: Aminoquinolines; Benzothiazoles; Bromocriptine; Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Ergolines; Ergoloid Mesylates; Female; Humans; Hyperprolactinemia; Indoles; Pergolide; Pramipexole; Thiazoles

2003
Dopamine resistance of prolactinomas.
    Pituitary, 2003, Volume: 6, Issue:1

    Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma

2003
Contemporary management of prolactinomas.
    Neurosurgical focus, 2004, Apr-15, Volume: 16, Issue:4

    Topics: Bromocriptine; Cabergoline; Contraindications; Diagnosis, Differential; Ergolines; Female; Humans; Hypophysectomy; Magnetic Resonance Imaging; Male; Pituitary Diseases; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma; Radiosurgery; Remission Induction

2004
[Prolactinoma and pregnancy].
    Akusherstvo i ginekologiia, 2004, Volume: 43 Suppl 2

    Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma

2004
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:5

    Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone

2005
Hyperprolactinemia: pathophysiology and management.
    Treatments in endocrinology, 2003, Volume: 2, Issue:1

    Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Estrogens; Female; Humans; Hyperprolactinemia; Male; Pergolide; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma; Radiotherapy; Surgical Procedures, Operative

2003
Current treatment issues in female hyperprolactinaemia.
    European journal of obstetrics, gynecology, and reproductive biology, 2006, Apr-01, Volume: 125, Issue:2

    Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Pregnancy; Prolactinoma

2006
Treatment of pituitary tumors: dopamine agonists.
    Endocrine, 2005, Volume: 28, Issue:1

    Topics: Adenoma; Bromocriptine; Cabergoline; Dopamine; Dopamine Agonists; Ergolines; Humans; Pituitary Neoplasms; Receptors, Dopamine

2005
Prolactinomas and pregnancy.
    Pituitary, 2005, Volume: 8, Issue:1

    Topics: Aminoquinolines; Bromocriptine; Cabergoline; Child; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma

2005
Pharmacologic resistance in prolactinoma patients.
    Pituitary, 2005, Volume: 8, Issue:1

    Topics: Bromocriptine; Cabergoline; Cell Proliferation; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Resistance; Ergolines; Estrogens; Female; Humans; Male; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Receptors, Dopamine D2

2005
Quinagolide--a valuable treatment option for hyperprolactinaemia.
    European journal of endocrinology, 2006, Volume: 154, Issue:2

    Topics: Administration, Oral; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Patient Compliance

2006
Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
    Nature clinical practice. Endocrinology & metabolism, 2006, Volume: 2, Issue:4

    Topics: Adenoma; Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Male; Prolactin; Prolactinoma; Sex Characteristics

2006
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
    Clinical therapeutics, 2006, Volume: 28, Issue:8

    Topics: Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Heart Valve Diseases; Humans; Indoles; Pergolide; Pulmonary Fibrosis; Receptors, Dopamine

2006
Clinical practice. Prolactinomas.
    The New England journal of medicine, 2010, Apr-01, Volume: 362, Issue:13

    Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma; Visual Fields

2010
Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis.
    Pituitary, 2011, Volume: 14, Issue:3

    Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Randomized Controlled Trials as Topic

2011
Prolactinoma in pregnancy.
    Best practice & research. Clinical endocrinology & metabolism, 2011, Volume: 25, Issue:6

    Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Fetus; Humans; Hyperprolactinemia; Infertility, Female; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma

2011
Anti-Parkinson's disease drugs and pharmacogenetic considerations.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:7

    Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline

2013
[Drug therapy for acromegaly].
    Orvosi hetilap, 2013, Sep-29, Volume: 154, Issue:39

    Topics: Acromegaly; Aminoquinolines; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Interdisciplinary Communication; Membrane Proteins; Octreotide; Patient Care Team; Peptides, Cyclic; Pituitary Neoplasms; Somatostatin

2013
Dopamine agonists in prevention of ovarian hyperstimulation syndrome.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2014, Volume: 30, Issue:12

    Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction

2014
Update on prolactinomas. Part 2: Treatment and management strategies.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2015, Volume: 22, Issue:10

    Topics: Bromocriptine; Cabergoline; Disease Management; Dopamine Agonists; Drug Administration Schedule; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neuroendoscopy; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma; Radiosurgery; Sphenoid Sinus

2015
A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters.
    Primary care diabetes, 2016, Volume: 10, Issue:1

    Topics: Animals; Biomarkers; Blood Glucose; Bromocriptine; Cabergoline; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dopamine Agonists; Ergolines; Humans; Hypoglycemic Agents; Risk Factors; Treatment Outcome

2016
Pharmacological lactation suppression with D2 receptor agonists and risk of postpartum psychosis: A systematic review.
    The Australian & New Zealand journal of obstetrics & gynaecology, 2016, Volume: 56, Issue:4

    Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Lactation; Psychoses, Substance-Induced; Receptors, Dopamine D2; Risk Factors

2016
Dopamine agonists for preventing ovarian hyperstimulation syndrome.
    The Cochrane database of systematic reviews, 2016, 11-30, Volume: 11

    Topics: Abortion, Spontaneous; Administration, Oral; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Reproductive Techniques, Assisted

2016
Current Medical Strategies in the Prevention of Ovarian Hyperstimulation Syndrome
    Acta clinica Croatica, 2017, Volume: 56, Issue:1

    Topics: Aminoquinolines; Bromocriptine; Buserelin; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Estradiol; Estrogens; Female; Fertility Agents, Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Oocyte Retrieval; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Rate; Progesterone; Progestins; Triptorelin Pamoate

2017
Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review.
    Metabolic brain disease, 2018, Volume: 33, Issue:3

    Topics: Adult; Bromocriptine; Cabergoline; Female; Humans; Hydranencephaly; Kidney Diseases; Male; Middle Aged; Prolactin; Prolactinoma; Sex Distribution; Treatment Outcome

2018
Management of Dopamine Agonist-Resistant Prolactinoma.
    Neuroendocrinology, 2019, Volume: 109, Issue:1

    Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Humans; Pituitary Neoplasms; Prolactinoma

2019
Dopamine agonists for preventing ovarian hyperstimulation syndrome.
    The Cochrane database of systematic reviews, 2021, 04-14, Volume: 4

    Topics: Abortion, Spontaneous; Administration, Oral; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Fertilization in Vitro; Humans; Live Birth; Ovarian Hyperstimulation Syndrome; Placebos; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Sperm Injections, Intracytoplasmic

2021
Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature.
    European journal of endocrinology, 2021, May-24, Volume: 185, Issue:1

    Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Female; Humans; Pituitary Apoplexy; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Prolactinoma; Tumor Burden; Young Adult

2021
The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis.
    BMC endocrine disorders, 2021, Nov-13, Volume: 21, Issue:1

    Topics: Bromocriptine; Cabergoline; Deprescriptions; Dopamine Agonists; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactinoma

2021
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aminoquinolines; beta-Arrestins; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Filamins; Growth Hormone-Secreting Pituitary Adenoma; Humans; Lisuride; MicroRNAs; Pergolide; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2

2021
Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus.
    Environmental science and pollution research international, 2022, Volume: 29, Issue:31

    Topics: Bromocriptine; Cabergoline; Diabetes Mellitus, Type 2; Dopamine Agonists; Humans; Hyperprolactinemia; Parkinson Disease; Restless Legs Syndrome

2022
Treatment of Prolactinoma.
    Medicina (Kaunas, Lithuania), 2022, Aug-13, Volume: 58, Issue:8

    Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Female; Humans; Pituitary Neoplasms; Pregnancy; Prolactinoma; Treatment Outcome

2022
Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy.
    Reviews in endocrine & metabolic disorders, 2022, Volume: 23, Issue:5

    Topics: Bromocriptine; Cabergoline; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms

2022
Metabolic effects of prolactin.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Bromocriptine; Cabergoline; Dopamine; Dopamine Agonists; Glucose; Humans; Hyperprolactinemia; Lipids; Male; Metabolic Syndrome; Obesity; Prolactin; Receptors, Dopamine; Receptors, Prolactin; Testosterone; Weight Gain

2022
The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis.
    Frontiers in endocrinology, 2023, Volume: 14

    Topics: Aminoquinolines; Bromocriptine; Cabergoline; Drug-Related Side Effects and Adverse Reactions; Humans; Hyperprolactinemia; Pituitary Neoplasms

2023
How to manage intolerance to dopamine agonist in patients with prolactinoma.
    Pituitary, 2023, Volume: 26, Issue:2

    Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma

2023
Diagnosis and Management of Pituitary Adenomas: A Review.
    JAMA, 2023, 04-25, Volume: 329, Issue:16

    Topics: Adenoma; Adrenocorticotropic Hormone; Adult; Bromocriptine; Cabergoline; Child; Female; Human Growth Hormone; Humans; Hypopituitarism; Pituitary Neoplasms; Pregnancy; Prolactinoma

2023

Trials

25 trial(s) available for bromocriptine and cabergoline

ArticleYear
Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. European Multicentre Study Group for Cabergoline in Lactation Inhibition.
    BMJ (Clinical research ed.), 1991, Jun-08, Volume: 302, Issue:6789

    Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agents; Double-Blind Method; Drug Administration Schedule; Ergolines; Female; Humans; Lactation; Pregnancy; Prospective Studies

1991
Cabergoline versus bromocriptine in suppression of lactation after cesarean delivery.
    Gynecologic and obstetric investigation, 1991, Volume: 31, Issue:2

    Topics: Administration, Oral; Adult; Bromocriptine; Cabergoline; Cesarean Section; Ergolines; Female; Humans; Lactation; Postpartum Period; Prolactin; Single-Blind Method

1991
Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.
    The Journal of clinical endocrinology and metabolism, 1988, Volume: 66, Issue:1

    Topics: Adolescent; Adult; Amenorrhea; Bromocriptine; Cabergoline; Clinical Trials as Topic; Ergolines; Female; Humans; Hyperprolactinemia; Kinetics; Male; Middle Aged; Prolactin

1988
[Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study].
    Presse medicale (Paris, France : 1983), 1995, Apr-29, Volume: 24, Issue:16

    Topics: Adolescent; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; France; Humans; Hyperprolactinemia; Middle Aged; Prolactin; Prospective Studies

1995
A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
    The New England journal of medicine, 1994, Oct-06, Volume: 331, Issue:14

    Topics: Adolescent; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agents; Double-Blind Method; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Prolactin

1994
Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
    European journal of endocrinology, 1996, Volume: 134, Issue:4

    Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Prolactinoma

1996
Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations.
    Neurology, 1996, Volume: 47, Issue:3

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Bromocriptine; Cabergoline; Double-Blind Method; Ergolines; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease

1996
Cabergoline for hyperprolactinemia.
    The Medical letter on drugs and therapeutics, 1997, Jun-20, Volume: 39, Issue:1003

    Topics: Abnormalities, Drug-Induced; Bromocriptine; Cabergoline; Costs and Cost Analysis; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Female; Humans; Intestinal Absorption; Prolactin

1997
Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.
    The Journal of clinical endocrinology and metabolism, 1998, Volume: 83, Issue:3

    Topics: Adult; Aminoquinolines; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Male; Middle Aged; Prospective Studies

1998
Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.
    European journal of endocrinology, 1998, Volume: 138, Issue:3

    Topics: Adult; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Ergolines; Follow-Up Studies; Hormones; Humans; Hyperprolactinemia; Libido; Male; Penile Erection; Prolactin; Semen; Time Factors

1998
[Treatment of hyperprolactinemic amenorrhea with cabergoline].
    Medicina, 1997, Volume: 57, Issue:6

    Topics: Adolescent; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agonists; Double-Blind Method; Drug Tolerance; Ergolines; Female; Humans; Hyperprolactinemia; Prolactin; Treatment Outcome

1997
Study of the change of prolactin and progesterone during dopaminergic agonist treatments in pseudopregnant bitches.
    Animal reproduction science, 2001, May-31, Volume: 66, Issue:3-4

    Topics: Animals; Bromocriptine; Cabergoline; Dog Diseases; Dogs; Dopamine Agonists; Ergolines; Female; Placebos; Progesterone; Prolactin; Pseudopregnancy

2001
Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Internal medicine (Tokyo, Japan), 2001, Volume: 40, Issue:9

    Topics: Adult; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Treatment Outcome

2001
Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:11

    Topics: Adenoma; Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Hypopituitarism; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Radioimmunoassay; Retrospective Studies

2001
Circulating nitric oxide changes throughout the menstrual cycle in healthy women and women affected by pathological hyperprolactinemia on dopamine agonist therapy.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2002, Volume: 16, Issue:5

    Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Estradiol; Female; Humans; Hyperprolactinemia; Luteal Phase; Menstrual Cycle; Nitric Oxide; Ovulation; Pituitary Neoplasms; Progesterone; Prolactinoma; Reference Values

2002
Coat colour changes associated with cabergoline administration in bitches.
    The Journal of small animal practice, 2003, Volume: 44, Issue:8

    Topics: Animals; Bromocriptine; Cabergoline; Dog Diseases; Dogs; Dopamine Agonists; Ergolines; Estrous Cycle; Female; Hair Color; Melanocyte-Stimulating Hormones; Pedigree; Pigmentation; Pseudopregnancy

2003
Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function.
    Pituitary, 2002, Volume: 5, Issue:4

    Topics: Adrenocorticotropic Hormone; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Follicle Stimulating Hormone; Humans; Hypopituitarism; Luteinizing Hormone; Male; Middle Aged; Pergolide; Pituitary Function Tests; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Testosterone; Thyrotropin

2002
Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2004, Volume: 111, Issue:6

    Topics: Aged; Antiparkinson Agents; Bromocriptine; Cabergoline; Ergolines; Humans; Parkinson Disease; Pergolide; Prospective Studies; Treatment Outcome

2004
[Comparative evaluation of effectiveness of treatment of hyperprolactinemia].
    Georgian medical news, 2007, Issue:142

    Topics: Adenoma; Adolescent; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Female; Humans; Hyperprolactinemia; Ovulation; Pituitary Neoplasms; Treatment Outcome

2007
Quality of life in women with microprolactinoma treated with dopamine agonists.
    Pituitary, 2008, Volume: 11, Issue:3

    Topics: Adult; Antineoplastic Agents; Brazil; Bromocriptine; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Health Status Indicators; Humans; Hyperprolactinemia; Middle Aged; Multivariate Analysis; Pituitary Neoplasms; Prolactin; Prolactinoma; Quality of Life; Reproducibility of Results; Surveys and Questionnaires; Treatment Outcome

2008
Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2009, Volume: 16, Issue:6

    Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Humans; Japan; Outcome Assessment, Health Care; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Time Factors; Treatment Outcome

2009
Cabergoline versus bromocriptine for symptomatic treatment of premenstrual mastalgia: a randomised, open-label study.
    European journal of obstetrics, gynecology, and reproductive biology, 2010, Volume: 150, Issue:2

    Topics: Adult; Analysis of Variance; Breast; Bromocriptine; Cabergoline; Drug Administration Schedule; Ergolines; Female; Hormone Antagonists; Humans; Middle Aged; Pain; Pain Measurement; Premenstrual Syndrome; Prolactin; Quality of Life; Severity of Illness Index; Treatment Outcome

2010
A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination.
    The Indian journal of medical research, 2010, Volume: 131

    Topics: Adult; Bromocriptine; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Insemination, Artificial

2010
Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:3

    Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3

2013
Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
    Basic & clinical pharmacology & toxicology, 2015, Volume: 116, Issue:3

    Topics: Adult; Blood Glucose; Bromocriptine; Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Insulin Resistance; Insulin-Like Growth Factor I; Lipids; Middle Aged; Prolactin; Risk Factors

2015

Other Studies

122 other study(ies) available for bromocriptine and cabergoline

ArticleYear
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
    The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:2

    Topics: Animals; Antiparkinson Agents; Binding Sites; Binding, Competitive; Cholinergic Antagonists; Cloning, Molecular; Cluster Analysis; Dopamine Agonists; Humans; Rats; Receptor, Muscarinic M1; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Receptors, Adrenergic, beta; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Histamine H1; Receptors, Muscarinic; Receptors, Neurotransmitter; Receptors, Serotonin

2002
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
    The European respiratory journal, 1992, Volume: 5, Issue:2

    Topics: Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Humans; Lung Diseases; Male; Middle Aged; Parkinson Disease; Pleural Effusion

1992
Cabergoline in the long-term therapy of hyperprolactinemic disorders.
    Acta endocrinologica, 1992, Volume: 126, Issue:6

    Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Drug Resistance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Menstruation Disturbances; Middle Aged; Ovulation; Pituitary Neoplasms; Prolactinoma

1992
In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine.
    European journal of pharmacology, 1990, Oct-23, Volume: 187, Issue:3

    Topics: Administration, Oral; Animals; Apomorphine; Brain Chemistry; Bromocriptine; Cabergoline; Dopamine Agents; Dose-Response Relationship, Drug; Ergolines; Female; In Vitro Techniques; Injections, Intravenous; Kinetics; Rats; Rats, Inbred Strains; Receptors, Dopamine

1990
New perspectives in medical management of hyperprolactinemia.
    Endocrinologia experimentalis, 1990, Volume: 24, Issue:1-2

    Topics: Adenoma; Bromocriptine; Cabergoline; Delayed-Action Preparations; Empty Sella Syndrome; Ergolines; Female; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms

1990
Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients.
    The Journal of clinical endocrinology and metabolism, 1989, Volume: 69, Issue:4

    Topics: Adenoma; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin

1989
Inhibitory effect of cabergoline on the development of estrogen-induced prolactin-secreting adenomas of the pituitary.
    European journal of pharmacology, 1988, Jun-22, Volume: 151, Issue:1

    Topics: Adenoma; Animals; Antineoplastic Agents; Body Weight; Bromocriptine; Cabergoline; DNA, Neoplasm; Ergolines; Estrogens; Female; Mitosis; Pituitary Neoplasms; Prolactin; Rats

1988
Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients.
    The Journal of clinical endocrinology and metabolism, 1986, Volume: 63, Issue:4

    Topics: Adult; Aged; Blood Pressure; Bromocriptine; Cabergoline; Ergolines; Female; Growth Hormone; Humans; Hyperprolactinemia; Male; Middle Aged; Time Factors

1986
Antitumor activity of FCE 21336, a new prolactin lowering drug, on the MXT mouse mammary carcinoma.
    Cancer letters, 1985, Sep-15, Volume: 28, Issue:2

    Topics: Animals; Antineoplastic Agents; Bromocriptine; Cabergoline; Dose-Response Relationship, Drug; Ergolines; Female; Mammary Neoplasms, Experimental; Mice; Prolactin

1985
Effect of octreotide on circulating IGF-I chromatographic profile: evidence for an inhibitory action on the formation of the 150-kDa ternary complex.
    Clinical endocrinology, 1995, Volume: 42, Issue:2

    Topics: Acromegaly; Adult; Bromocriptine; Cabergoline; Carrier Proteins; Ergolines; Growth Hormone; Humans; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Middle Aged; Octreotide

1995
In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors.
    Endocrine journal, 1995, Volume: 42, Issue:2

    Topics: Animals; Antineoplastic Agents; Bromocriptine; Cabergoline; Cytoplasmic Granules; Dopamine Agonists; Endoplasmic Reticulum; Ergolines; Estradiol; Female; Microscopy, Electron; Organ Size; Pituitary Neoplasms; Prolactin; Rats; Rats, Inbred F344

1995
Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: in vitro culture studies.
    Endocrine journal, 1995, Volume: 42, Issue:3

    Topics: Animals; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Estradiol; Female; Pituitary Neoplasms; Prolactin; Rats; Rats, Inbred F344; Tumor Cells, Cultured

1995
X-ray crystal structure and conformational analysis of N-(3-dimethylaminopropyl)-N-(ethylaminocarbonyl)-6-(2-propenyl)er goline -8 beta-carboxamide (Cabergoline): comparison with bromocriptine and lisuride and a hypothesis for its high dopaminergic activi
    Farmaco (Societa chimica italiana : 1989), 1995, Volume: 50, Issue:3

    Topics: Bromocriptine; Cabergoline; Crystallography, X-Ray; Dopamine Agonists; Ergolines; Lisuride; Molecular Conformation; Structure-Activity Relationship

1995
Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to plasma levodopa profile.
    Annals of neurology, 1995, Volume: 37, Issue:1

    Topics: Aged; Bromocriptine; Cabergoline; Chorea; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Monitoring, Physiologic; Parkinson Disease; Pergolide; Sweating

1995
Cabergoline treated hyperprolactinaemia results in pregnancy in a bromocriptine intolerant patient after seventeen years of infertility.
    British journal of obstetrics and gynaecology, 1994, Volume: 101, Issue:4

    Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Pregnancy

1994
Progress in the management of hyperprolactinemia.
    The New England journal of medicine, 1994, Oct-06, Volume: 331, Issue:14

    Topics: Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Hyperprolactinemia

1994
Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics.
    Fertility and sterility, 1996, Volume: 65, Issue:2

    Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Vagina

1996
Differential effects of three dopamine receptor agonists in MPTP-treated monkeys.
    Journal of neural transmission. Parkinson's disease and dementia section, 1995, Volume: 10, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Macaca fascicularis; Parkinson Disease, Secondary; Pergolide

1995
Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats.
    Biological & pharmaceutical bulletin, 1996, Volume: 19, Issue:9

    Topics: Animals; Benzazepines; Binding, Competitive; Bromocriptine; Cabergoline; Dopamine Agonists; Dopamine Antagonists; Ergolines; In Vitro Techniques; Male; Pergolide; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Stereotyped Behavior

1996
Effect of different dopaminergic agents in the treatment of acromegaly.
    The Journal of clinical endocrinology and metabolism, 1997, Volume: 82, Issue:2

    Topics: Acromegaly; Adult; Aminoquinolines; Bromocriptine; Cabergoline; Delayed-Action Preparations; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Male; Middle Aged; Prolactin

1997
Late development of resistance to bromocriptine in a patient with macroprolactinoma.
    Hormone research, 1998, Volume: 49, Issue:5

    Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma

1998
New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline.
    European journal of pharmacology, 1999, Feb-26, Volume: 368, Issue:1

    Topics: Animals; Anovulation; Bromocriptine; Cabergoline; Callithrix; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Ergolines; Estradiol; Female; Hyperprolactinemia; Menstrual Cycle; Progesterone; Prolactin; Sulpiride; Time Factors

1999
Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
    The Journal of clinical endocrinology and metabolism, 1999, Volume: 84, Issue:7

    Topics: Adenoma; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Drug Tolerance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Retrospective Studies; Sex Characteristics

1999
Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
    Clinical endocrinology, 2000, Volume: 52, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Analysis of Variance; Biomarkers; Bone Density; Bone Remodeling; Bromocriptine; Cabergoline; Case-Control Studies; Collagen; Collagen Type I; Dopamine Agonists; Ergolines; Female; Femur Neck; Humans; Longitudinal Studies; Lumbar Vertebrae; Male; Middle Aged; Osteocalcin; Osteoporosis; Peptides; Pituitary Neoplasms; Prolactinoma; Regression Analysis

2000
Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
    Journal of neural transmission (Vienna, Austria : 1996), 2000, Volume: 107, Issue:10

    Topics: Animals; Benzothiazoles; Brain; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Indoles; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Dopamine D1; Receptors, Dopamine D2; Thiazoles

2000
Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
    Journal of endocrinological investigation, 2000, Volume: 23, Issue:11

    Topics: Adult; Antipsychotic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Hypogonadism; Male; Middle Aged; Prolactin; Psychotic Disorders; Risperidone

2000
Treatment versus no treatment of transient hyperprolactinemia in patients undergoing intracytoplasmic sperm injection programs.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2000, Volume: 14, Issue:6

    Topics: Adult; Bromocriptine; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Embryo Transfer; Ergolines; Estradiol; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Hyperprolactinemia; Luteolytic Agents; Oocytes; Prolactin; Retrospective Studies; Sperm Injections, Intracytoplasmic; Treatment Outcome; Triptorelin Pamoate

2000
Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases.
    Journal of endocrinological investigation, 2001, Volume: 24, Issue:2

    Topics: Acromegaly; Adenoma; Adolescent; Amenorrhea; Bromocriptine; Cabergoline; Child; Ergolines; Female; Headache; Human Growth Hormone; Humans; Male; Neoplasm Recurrence, Local; Octreotide; Pituitary Neoplasms; Prolactinoma; Puberty, Delayed; Radiotherapy; Treatment Outcome; Vision Disorders; Visual Fields

2001
Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method.
    The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:6

    Topics: Adult; Bromocriptine; Cabergoline; Cohort Studies; Ergolines; Female; Fertility; Headache; Humans; Magnetic Resonance Imaging; Medical Records; Menstruation; Menstruation Disturbances; Middle Aged; Pituitary Gland; Polyethylene Glycols; Prolactin; Tomography, X-Ray Computed

2001
Successful treatment of a large macroprolactinoma with cabergoline during pregnancy.
    Pituitary, 2001, Volume: 4, Issue:3

    Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma

2001
The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
    The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:10

    Topics: Adult; Anastrozole; Aromatase Inhibitors; Bromocriptine; Cabergoline; Dopamine Agonists; Enzyme Inhibitors; Ergolines; Hormone Replacement Therapy; Humans; Magnetic Resonance Imaging; Male; Nitriles; Pituitary Neoplasms; Prolactin; Prolactinoma; Sexual Dysfunction, Physiological; Testosterone; Treatment Outcome; Triazoles

2002
Prolactinomas, dopamine agonists and headache: two case reports.
    European journal of neurology, 2003, Volume: 10, Issue:2

    Topics: Adult; Amenorrhea; Anti-Inflammatory Agents, Non-Steroidal; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Headache; Humans; Indomethacin; Magnetic Resonance Imaging; Pituitary Neoplasms; Prolactin; Prolactinoma; Radiography

2003
Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes.
    Life sciences, 2003, Jun-20, Volume: 73, Issue:5

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Astrocytes; Blotting, Northern; Brain-Derived Neurotrophic Factor; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Ergolines; Glial Cell Line-Derived Neurotrophic Factor; Mice; Mice, Inbred ICR; Nerve Growth Factor; Nerve Growth Factors; Pergolide; Receptors, Dopamine D1; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors

2003
[Clinical and therapeutic aspects of prolactinoma in men].
    Arquivos de neuro-psiquiatria, 2003, Volume: 61, Issue:4

    Topics: Adolescent; Adult; Age of Onset; Biomarkers; Bromocriptine; Cabergoline; Chi-Square Distribution; Dopamine Agonists; Ergolines; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Pituitary Neoplasms; Prolactin; Prolactinoma; Statistics, Nonparametric; Treatment Outcome

2003
Prolactinoma presenting as painful postganglionic Horner syndrome.
    Neurology, 2004, Apr-27, Volume: 62, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Bromocriptine; Cabergoline; Carotid Arteries; Dopamine Agonists; Ergolines; Horner Syndrome; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Migraine Disorders; Neoplasm Recurrence, Local; p-Hydroxyamphetamine; Pituitary Neoplasms; Prolactin; Prolactinoma; Remission Induction

2004
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:11

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Therapeutic Equivalency; Thiazoles

2004
Cardiopulmonary complications of ergot-derivative dopamine agonists.
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:10

    Topics: Antipsychotic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Pergolide; Pulmonary Fibrosis; Risperidone

2004
Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:12

    Topics: Aortic Valve; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Fibrosis; Heart Valve Diseases; Humans; Parkinson Disease; Pergolide

2004
Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.
    Hormone research, 2004, Volume: 62, Issue:6

    Topics: Adenoma; Adrenalectomy; Adrenocorticotropic Hormone; Adult; Bromocriptine; Cabergoline; Cyproheptadine; Dopamine Agonists; Ergolines; Female; Hormone Replacement Therapy; Humans; Magnetic Resonance Imaging; Nelson Syndrome; Pituitary Neoplasms

2004
Dopamine agonist treatment before and after the birth reduces prolactin concentration but does not impair paternal responsiveness in Djungarian hamsters, Phodopus campbelli.
    Hormones and behavior, 2005, Volume: 47, Issue:3

    Topics: Animals; Bromocriptine; Cabergoline; Cricetinae; Dopamine Agonists; Ergolines; Female; Male; Parturition; Paternal Behavior; Phodopus; Pregnancy; Prolactin; Receptors, Dopamine D1; Receptors, Dopamine D2

2005
Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly.
    European journal of endocrinology, 2005, Volume: 152, Issue:4

    Topics: Acromegaly; Adult; Aged; Aged, 80 and over; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Prolactin; Retrospective Studies; Somatostatin

2005
The clinical characteristics of headache in patients with pituitary tumours.
    Brain : a journal of neurology, 2005, Volume: 128, Issue:Pt 8

    Topics: Adenoma; Adult; Aminoquinolines; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Disability Evaluation; Dopamine Agonists; Ergolines; Female; Headache; Humans; Male; Migraine Disorders; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Severity of Illness Index; Somatostatin; Time Factors

2005
The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
    Journal of pediatric hematology/oncology, 2005, Volume: 27, Issue:6

    Topics: Bromocriptine; Cabergoline; Child; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Treatment Outcome

2005
Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas.
    Clinical endocrinology, 2005, Volume: 63, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome

2005
Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Pituitary, 2005, Volume: 8, Issue:1

    Topics: Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Remission Induction; Retrospective Studies; Treatment Outcome

2005
Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy.
    Nature clinical practice. Endocrinology & metabolism, 2006, Volume: 2, Issue:3

    Topics: Adolescent; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma

2006
Clinical presentation and response to therapy in patients with massive prolactin hypersecretion.
    Pituitary, 2007, Volume: 10, Issue:1

    Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Testosterone

2007
Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome.
    Clinical endocrinology, 2007, Volume: 66, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Agents, Hormonal; Body Height; Body Mass Index; Bromocriptine; Cabergoline; Combined Modality Therapy; Ergolines; Female; Growth Hormone; Growth Hormone-Secreting Pituitary Adenoma; Headache; Hormone Antagonists; Humans; Insulin Resistance; Insulin-Like Growth Factor I; Male; Menstruation Disturbances; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Retrospective Studies; Somatostatin; Treatment Outcome

2007
Prolactin and autoimmune diseases in humans.
    Acta bio-medica : Atenei Parmensis, 2007, Volume: 78 Suppl 1

    Topics: Aminoquinolines; Animals; Arthritis, Rheumatoid; Autoimmune Diseases; Bromocriptine; Cabergoline; Cyclosporine; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Ergolines; Female; Humans; Hyperprolactinemia; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Male; Mice; Mice, Knockout; Penicillamine; Prednisone; Prolactin; Rats; Receptors, Prolactin

2007
Dopaminergic treatment of nonfunctioning pituitary adenomas.
    Nature clinical practice. Endocrinology & metabolism, 2007, Volume: 3, Issue:8

    Topics: Adenoma; Bromocriptine; Cabergoline; Dopamine Agents; Dopamine Agonists; Ergolines; Humans; Pituitary Neoplasms; Prolactin

2007
Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
    Surgical neurology, 2008, Volume: 69, Issue:1

    Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactinoma; Treatment Outcome

2008
The frequency of cardiac valvular regurgitation in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2008, May-15, Volume: 23, Issue:7

    Topics: Aged; Aortic Valve Insufficiency; Azepines; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Mitral Valve Insufficiency; Parkinson Disease; Pergolide; Pramipexole; Prevalence

2008
Clinical profile and long term follow up of children and adolescents with prolactinomas.
    Pituitary, 2009, Volume: 12, Issue:3

    Topics: Adolescent; Amenorrhea; Bromocriptine; Cabergoline; Child; Dopamine Agonists; Ergolines; Female; Galactorrhea; Humans; Male; Pregnancy; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome; Young Adult

2009
High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2009, Volume: 116, Issue:2

    Topics: Age Factors; Aged; Benzothiazoles; Bromocriptine; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Hypertension; Male; Parkinson Disease; Pergolide; Pramipexole; Risk Factors

2009
Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
    Movement disorders : official journal of the Movement Disorder Society, 2009, Jan-15, Volume: 24, Issue:1

    Topics: Aged; Aged, 80 and over; Apomorphine; Benzothiazoles; Bromocriptine; Cabergoline; Databases, Factual; Dopamine Agonists; Endomyocardial Fibrosis; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Indoles; Male; Middle Aged; Pergolide; Pericarditis; Pleural Diseases; Pramipexole; Pulmonary Fibrosis; Retroperitoneal Fibrosis; Tetrahydronaphthalenes; Thiophenes; United States

2009
Dopamine agonists and hyperprolactinaemia.
    BMJ (Clinical research ed.), 2009, Mar-03, Volume: 338

    Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia

2009
Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
    Internal medicine journal, 2009, Volume: 39, Issue:4

    Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Parkinson Disease; Pergolide; Prolactin; Serotonin 5-HT2 Receptor Agonists; Ultrasonography

2009
Non-surgical management of cystic prolactinomas.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2009, Volume: 16, Issue:11

    Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Follow-Up Studies; Gadolinium; Hormones; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Young Adult

2009
Comparative efficacy of bromocriptine, cabergoline and thyroxine in inducing oestrus in bitches.
    Veterinary research communications, 2010, Volume: 34, Issue:1

    Topics: Animals; Bromocriptine; Cabergoline; Dogs; Ergolines; Estrous Cycle; Female; Fertilization; Hormone Antagonists; Litter Size; Progesterone; Prolactin; Thyroxine

2010
Management of prolactinomas in Brazil: an electronic survey.
    Pituitary, 2010, Volume: 13, Issue:3

    Topics: Brazil; Bromocriptine; Cabergoline; Data Collection; Dopamine Agonists; Ergolines; Female; Humans; Pregnancy; Prolactinoma

2010
Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
    The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:6

    Topics: Adult; Birth Weight; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Drug Resistance; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Magnetic Resonance Imaging; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Progesterone; Prolactin; Prolactinoma

2010
Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2010, Volume: 26, Issue:7

    Topics: Adult; Bromocriptine; Cabergoline; Databases, Factual; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Pregnancy; Pregnancy Rate; Retrospective Studies; Sperm Injections, Intracytoplasmic; Treatment Outcome

2010
BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.
    Obesity (Silver Spring, Md.), 2011, Volume: 19, Issue:4

    Topics: Adult; Aftercare; Aged; Blood Glucose; Body Composition; Body Mass Index; Body Weight; Bromocriptine; Cabergoline; Cholesterol, HDL; Cholesterol, LDL; Dopamine Agonists; Ergolines; Female; Humans; Insulin; Insulin Resistance; Leptin; Male; Metabolic Syndrome; Metabolome; Middle Aged; Obesity; Prevalence; Prolactinoma; Waist Circumference; Weight Gain; Young Adult

2011
Effect of dopaminergic drug treatment on surgical findings in prolactinomas.
    Pituitary, 2011, Volume: 14, Issue:1

    Topics: Adenoma; Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Child; Dopamine Agents; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Young Adult

2011
Disorganized schizophrenia does not deteriorate with dopamine agonists cabergoline and bromocriptine used for ablactation.
    Pharmacopsychiatry, 2011, Volume: 44, Issue:2

    Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Lactation; Mastitis; Schizophrenia, Disorganized

2011
Pituitary tumors: cabergoline versus bromocriptine: a meta-analysis?
    Nature reviews. Endocrinology, 2011, Volume: 7, Issue:5

    Topics: Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Humans; Meta-Analysis as Topic; Pituitary Neoplasms; Treatment Outcome

2011
Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience.
    Pituitary, 2012, Volume: 15, Issue:1

    Topics: Adolescent; Adult; Aged; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prolactinoma; Treatment Outcome; Young Adult

2012
A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas.
    Pituitary, 2012, Volume: 15, Issue:1

    Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Prolactinoma

2012
[Prescription of ergot derivatives for lactation inhibition in France: Current practices].
    Journal de gynecologie, obstetrique et biologie de la reproduction, 2012, Volume: 41, Issue:2

    Topics: Bromocriptine; Cabergoline; Dihydroergocryptine; Dopamine Agonists; Ergolines; Ergot Alkaloids; Female; France; Humans; Lactation; Lisuride; Practice Patterns, Physicians'; Prolactin; Surveys and Questionnaires

2012
No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma.
    Clinical endocrinology, 2012, Volume: 77, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Cross-Sectional Studies; Echocardiography; Ergolines; Female; Humans; Male; Middle Aged; Prolactinoma; Retrospective Studies; Tricuspid Valve Insufficiency; Young Adult

2012
Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
    European journal of endocrinology, 2012, Volume: 167, Issue:1

    Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Prospective Studies

2012
[Gender effect on cardiomyopathy].
    Giornale italiano di cardiologia (2006), 2012, Volume: 13, Issue:6

    Topics: Bromocriptine; Cabergoline; Cardiomyopathies; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Cardiomyopathy, Restrictive; Dopamine Agonists; Ergolines; Evidence-Based Medicine; Female; Genetic Counseling; Humans; Phenotype; Pregnancy; Pregnancy Complications, Cardiovascular; Prognosis; Prolactin; Risk Assessment; Risk Factors; Sex Factors; Treatment Outcome

2012
Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
    Neuro endocrinology letters, 2012, Volume: 33, Issue:3

    Topics: Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Retrospective Studies; Risk Factors; Ultrasonography; Young Adult

2012
Medically treated prolactin-secreting pituitary adenomas: when should we operate?
    British journal of neurosurgery, 2013, Volume: 27, Issue:1

    Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Female; Hormone Antagonists; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Postmenopause; Premenopause; Prolactinoma; Prospective Studies; Retrospective Studies; Sphenoid Bone; Time Factors; Treatment Failure

2013
Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases.
    Pituitary, 2013, Volume: 16, Issue:3

    Topics: Acromegaly; Adult; Bromocriptine; Cabergoline; Databases, Factual; Ergolines; Female; Human Growth Hormone; Humans; Male; Middle Aged; Octreotide; Peptides, Cyclic; Retrospective Studies; Somatostatin; United States

2013
Short-term pharmacological suppression of the hyperprolactinemia of infertile hCG-overproducing female mice persistently restores their fertility.
    Endocrinology, 2012, Volume: 153, Issue:12

    Topics: Animals; Bromocriptine; Cabergoline; Chorionic Gonadotropin; Disease Models, Animal; Ergolines; Female; Fertility; Gene Expression Regulation; Humans; Hyperprolactinemia; Infertility; Mice; Mice, Transgenic; Ovulation; Phenotype; Time Factors

2012
Risk of thromboembolic events in patients with prolactinomas compared with patients with nonfunctional pituitary adenomas.
    Pituitary, 2013, Volume: 16, Issue:4

    Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Female; Humans; Male; Middle Aged; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Thromboembolism; Young Adult

2013
Hyperprolactinemia in children: clinical features and long-term results.
    Journal of pediatric endocrinology & metabolism : JPEM, 2012, Volume: 25, Issue:11-12

    Topics: Adolescent; Bromocriptine; Cabergoline; Child; Combined Modality Therapy; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Treatment Outcome

2012
[Visual outcome in patients with macroprolactinoma treated with dopamine agonists].
    Revista medica de Chile, 2013, Volume: 141, Issue:6

    Topics: Adolescent; Adult; Bromocriptine; Cabergoline; Child; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prolactinoma; Retrospective Studies; Vision Disorders; Visual Acuity; Visual Fields; Young Adult

2013
Occlusal treatment with bite splint improves dyskinesia in Parkinson's disease patient: a case report.
    The Bulletin of Tokyo Dental College, 2013, Volume: 54, Issue:3

    Topics: Activities of Daily Living; Antiparkinson Agents; Bromocriptine; Cabergoline; Clonidine; Dyskinesias; Ergolines; Female; Hand Strength; Humans; Levodopa; Middle Aged; Motor Skills; Occlusal Splints; Parkinson Disease; Posture

2013
[Inhibition of lactation: end to the bromocriptin, long life to the carbergolin?].
    Gynecologie, obstetrique & fertilite, 2014, Volume: 42, Issue:4

    Topics: Bromocriptine; Cabergoline; Cardiovascular Diseases; Ergolines; Female; France; Hormone Antagonists; Humans; Lactation

2014
Women with prolactinomas presented at the postmenopausal period.
    Endocrine, 2014, Volume: 47, Issue:3

    Topics: Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Follicle Stimulating Hormone; Humans; Hyperprolactinemia; Luteinizing Hormone; Middle Aged; Pituitary Neoplasms; Postmenopause; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome

2014
Young female with acromegaloid features and pituitary macroadenoma: what is your diagnosis?
    Boletin de la Asociacion Medica de Puerto Rico, 2014, Volume: 106, Issue:1

    Topics: Acanthosis Nigricans; Acromegaly; Adult; Bromocriptine; Cabergoline; Diagnosis, Differential; Ergolines; Female; Gastrointestinal Diseases; Hirsutism; Human Growth Hormone; Humans; Hyperprolactinemia; Insulin; Insulin Resistance; Insulin-Like Growth Factor I; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Prognathism; Prolactinoma

2014
A case of iatrogenic severe mitral regurgitation.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2013, Volume: 80, Issue:3

    Topics: Antineoplastic Agents; Bromocriptine; Cabergoline; Drug Therapy, Combination; Ergolines; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hormone Antagonists; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Pituitary Neoplasms; Prolactinoma; Treatment Outcome

2013
Comparison of efficacy of bromocriptine and cabergoline to GnRH agonist in a rat endometriosis model.
    Archives of gynecology and obstetrics, 2015, Volume: 291, Issue:5

    Topics: Adult; Animals; Antineoplastic Agents; Bromocriptine; Cabergoline; Disease Models, Animal; Dopamine Agonists; Endometriosis; Endometrium; Ergolines; Female; Gonadotropin-Releasing Hormone; Humans; Laparotomy; Leuprolide; Prospective Studies; Random Allocation; Rats; Rats, Wistar; Triptorelin Pamoate

2015
Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience.
    Journal of endocrinological investigation, 2015, Volume: 38, Issue:4

    Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult

2015
Treatment outcome results from the Bulgarian Acromegaly Database: adjuvant dopamine agonist therapy is efficient in less than one fifth of non-irradiated patients.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2015, Volume: 123, Issue:1

    Topics: Acromegaly; Adolescent; Adult; Aged; Bromocriptine; Bulgaria; Cabergoline; Child; Databases, Factual; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Humans; Male; Middle Aged; Radiotherapy; Remission Induction; Retrospective Studies; Somatostatin

2015
[Pituitary apoplexy in a pregnant woman with cystic microprolactinoma].
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2015, Volume: 62, Issue:4

    Topics: Adult; Bromocriptine; Cabergoline; Combined Modality Therapy; Contraindications; Dopamine Agonists; Drug Substitution; Ergolines; Female; Headache; Hormone Replacement Therapy; Humans; Hydrocortisone; Hypophysectomy; Infant, Newborn; Male; Pituitary Apoplexy; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Prolactinoma; Thyroxine; Vision Disorders

2015
Different Effects of Metformin on the Hypothalamic-Pituitary-Thyroid Axis in Bromocriptine- and Cabergoline-treated Patients with Hashimoto's Thyroiditis and Glucose Metabolism Abnormalities.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2015, Volume: 123, Issue:9

    Topics: Adult; Bromocriptine; Cabergoline; Ergolines; Female; Glucose Metabolism Disorders; Hashimoto Disease; Humans; Hypothalamo-Hypophyseal System; Metformin; Middle Aged; Thyroid Gland

2015
Cost-Effectiveness Analysis of Microscopic and Endoscopic Transsphenoidal Surgery Versus Medical Therapy in the Management of Microprolactinoma in the United States.
    World neurosurgery, 2016, Volume: 87

    Topics: Adult; Aged; Bromocriptine; Cabergoline; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Ergolines; Female; Health Care Costs; Hormone Antagonists; Humans; Hyperprolactinemia; Life Expectancy; Male; Medicare; Microsurgery; Middle Aged; Monte Carlo Method; Neuroendoscopy; Pituitary Neoplasms; Prolactinoma; Quality-Adjusted Life Years; Sphenoid Sinus; Time Factors; Treatment Outcome; United States

2016
Inhibiting the onset of lactation. Is cabergoline an alternative to bromocriptine?
    Prescrire international, 2015, Volume: 24, Issue:165

    Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Europe; Female; France; Humans; Lactation

2015
Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Pituitary, 2016, Volume: 19, Issue:3

    Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Deprescriptions; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Time Factors; Tumor Burden; Young Adult

2016
Prolactinomas: evolution after menopause.
    Archives of endocrinology and metabolism, 2016, Volume: 60, Issue:1

    Topics: Adenoma; Adult; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Menopause; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome; Withholding Treatment

2016
Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
    Pituitary, 2016, Volume: 19, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Child; Ergolines; Female; Galactorrhea; Headache; Hormone Antagonists; Humans; Male; Middle Aged; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Sexual Dysfunction, Physiological; Treatment Outcome; Tumor Burden; Vision Disorders; Young Adult

2016
Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists.
    European journal of endocrinology, 2016, Volume: 175, Issue:1

    Topics: Adenoma; Adult; Aged; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Receptors, Dopamine; Receptors, Estrogen; Treatment Outcome

2016
Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
    Endocrine, 2017, Volume: 55, Issue:2

    Topics: Adult; Aged; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hypogonadism; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Sexual Dysfunction, Physiological

2017
SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:1

    Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Remission Induction; Retrospective Studies; Treatment Failure; Treatment Outcome; Tumor Burden; Young Adult

2017
10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
    Endocrine, 2017, Volume: 55, Issue:1

    Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Humans; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome; Young Adult

2017
Macroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes.
    Obstetrics and gynecology, 2017, Volume: 129, Issue:1

    Topics: Adenoma; Adult; Amenorrhea; Antineoplastic Agents; Bromocriptine; Cabergoline; Case-Control Studies; Cesarean Section; Dopamine Agonists; Ergolines; Female; Galactorrhea; Humans; Incidence; Pituitary Neoplasms; Pre-Eclampsia; Preconception Care; Pregnancy; Pregnancy Complications, Neoplastic; Premature Birth; Prolactinoma; Prospective Studies; Stillbirth; United Kingdom; Vision Disorders; Young Adult

2017
MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
    European journal of endocrinology, 2017, Volume: 176, Issue:3

    Topics: Adult; Aminoquinolines; Belgium; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; France; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies

2017
Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.
    Pituitary, 2017, Volume: 20, Issue:4

    Topics: Adolescent; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Prolactin; Prolactinoma; Retrospective Studies; Young Adult

2017
Pregnancy and Tumor Outcomes in Women with Prolactinoma.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2017, Volume: 125, Issue:10

    Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Outcome Assessment, Health Care; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma; Retrospective Studies; Young Adult

2017
Best candidates for dopamine agonist withdrawal in patients with prolactinomas.
    Pituitary, 2017, Volume: 20, Issue:5

    Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prolactinoma; Retrospective Studies; Young Adult

2017
The efficacy of medical treatment in patients with acromegaly in clinical practice.
    Endocrine journal, 2018, Jan-30, Volume: 65, Issue:1

    Topics: Acromegaly; Adenoma; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Female; Follow-Up Studies; Growth Hormone-Secreting Pituitary Adenoma; Hospitals, University; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Neoplasm Grading; Republic of Korea; Retrospective Studies; Somatostatin; Tumor Burden

2018
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
    Endocrinologia, diabetes y nutricion, 2017, Volume: 64, Issue:10

    Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined Modality Therapy; Dacarbazine; Drug Substitution; Ergolines; Fatal Outcome; Headache; Humans; Hyperprolactinemia; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Proton Therapy; Temozolomide

2017
The Expression of Dopamine Receptors Gene and their Potential Role in Targeting Breast Cancer Cells with Selective Agonist and Antagonist Drugs. Could it be the Novel Insight to Therapy?
    Current drug discovery technologies, 2019, Volume: 16, Issue:2

    Topics: Adult; Apoptosis; Breast Neoplasms; Bromocriptine; Cabergoline; Cell Line, Tumor; Cell Proliferation; Dopamine; Dopamine Agonists; Dopamine Antagonists; Female; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Middle Aged; Neoplasm Staging; Receptors, Dopamine; Receptors, Estrogen; Receptors, Progesterone; Remoxipride

2019
Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.
    Clinical endocrinology, 2018, Volume: 89, Issue:3

    Topics: Adolescent; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Menopause; Postmenopause; Prolactin; Prolactinoma; Retrospective Studies; Withholding Treatment; Young Adult

2018
Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.
    Endocrine, 2018, Volume: 62, Issue:2

    Topics: Adolescent; Adult; Bromocriptine; Cabergoline; Drug Resistance, Neoplasm; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Invasiveness; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Failure; Tumor Burden; Young Adult

2018
Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.
    Cell death & disease, 2019, 04-18, Volume: 10, Issue:5

    Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Bromocriptine; Cabergoline; Cell Line, Tumor; Early Growth Response Protein 1; Extracellular Signal-Regulated MAP Kinases; Female; Mice; Mice, Nude; Microtubule-Associated Proteins; Pituitary Neoplasms; Prolactinoma; Proto-Oncogene Proteins c-akt; Rats; RNA Interference; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases

2019
Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
    World neurosurgery, 2019, Volume: 129

    Topics: Adult; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Sex Factors; Treatment Failure; Tumor Burden

2019
Development of a novel patient-reported measure for acromegaly: the Acro-TSQ.
    Pituitary, 2019, Volume: 22, Issue:6

    Topics: Acromegaly; Adult; Bromocriptine; Cabergoline; Female; Human Growth Hormone; Humans; Interviews as Topic; Male; Middle Aged; Octreotide; Peptides, Cyclic; Personal Satisfaction; Somatostatin; Surveys and Questionnaires

2019
An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists.
    The Australian & New Zealand journal of obstetrics & gynaecology, 2020, Volume: 60, Issue:3

    Topics: Abortion, Spontaneous; Adenoma; Adolescent; Adult; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Female; Humans; Infertility; Lactation; Pituitary Neoplasms; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma; Retrospective Studies; Young Adult

2020
Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
    Endocrine journal, 2020, Feb-28, Volume: 67, Issue:2

    Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Chemical and Drug Induced Liver Injury; Child; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hypoglycemia; Insulin-Like Growth Factor I; Japan; Male; Middle Aged; Neurosurgical Procedures; Octreotide; Peptides, Cyclic; Product Surveillance, Postmarketing; Radiotherapy; Receptors, Somatotropin; Somatostatin; Tumor Burden; Young Adult

2020
Prevalence, incidence, comorbidities, and treatment patterns among Japanese patients with acromegaly: a descriptive study using a nationwide claims database.
    Endocrine journal, 2020, Oct-28, Volume: 67, Issue:10

    Topics: Acromegaly; Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Comorbidity; Dopamine Agonists; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hyperlipidemias; Hypertension; Incidence; Japan; Male; Middle Aged; Neurosurgical Procedures; Octreotide; Peptides, Cyclic; Prevalence; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Somatostatin; Young Adult

2020
Therapeutic activity of sarpogrelate and dopamine D
    BMC pharmacology & toxicology, 2021, 10-26, Volume: 22, Issue:1

    Topics: Animals; Blood Glucose; Bromocriptine; Cabergoline; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dopamine Agonists; Drug Therapy, Combination; Isoenzymes; Kidney; L-Lactate Dehydrogenase; Male; Myocardial Infarction; Myocardium; Rats, Wistar; Serotonin 5-HT2 Receptor Antagonists; Succinates; Troponin I; Tumor Necrosis Factor-alpha

2021
ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathways.
    Endocrine-related cancer, 2021, 12-13, Volume: 29, Issue:2

    Topics: AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Bromocriptine; Cabergoline; Drug Resistance, Neoplasm; Drug Synergism; Early Growth Response Protein 1; Furans; Humans; Pituitary Neoplasms; Prolactinoma; TOR Serine-Threonine Kinases

2021
Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas.
    Journal francais d'ophtalmologie, 2022, Volume: 45, Issue:5

    Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Female; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Vision Disorders; Visual Fields

2022
The Inhibitory Effect of Selected D
    Cells, 2022, 04-02, Volume: 11, Issue:7

    Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Bromocriptine; Cabergoline; Dopamine Agonists; Hypoxia; Larva; Neovascularization, Pathologic; Pergolide; Vascular Endothelial Growth Factor A; Zebrafish

2022
Cabergoline treatment promotes myocardial recovery in peripartum cardiomyopathy.
    ESC heart failure, 2023, Volume: 10, Issue:1

    Topics: Animals; Bromocriptine; Cabergoline; Cardiomyopathies; Dopamine Agonists; Female; Heart Failure; Mice; MicroRNAs; Myocytes, Cardiac; Peripartum Period; Pregnancy; Prolactin; Ventricular Dysfunction, Left

2023
Long-term low-dose cabergoline usage: Another association with cardiac valvulopathy.
    Echocardiography (Mount Kisco, N.Y.), 2023, Volume: 40, Issue:1

    Topics: Bromocriptine; Cabergoline; Ergolines; Heart Valve Diseases; Humans; Middle Aged; Pituitary Neoplasms

2023
Italian Guidelines for the Management of Prolactinomas.
    Endocrine, metabolic & immune disorders drug targets, 2023, Volume: 23, Issue:12

    Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Pituitary Neoplasms; Prolactin; Prolactinoma

2023